相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet et al.
HEPATOLOGY (2021)
Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea
Min Jin Lee et al.
INVESTIGATIONAL NEW DRUGS (2021)
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan
Sadahisa Ogasawara et al.
INVESTIGATIONAL NEW DRUGS (2020)
Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka et al.
ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study
Hyung-Don Kim et al.
LIVER INTERNATIONAL (2020)
Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade
Tomoko Aoki et al.
CANCERS (2020)
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis
Atsushi Hiraoka et al.
HEPATOLOGY RESEARCH (2019)
Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment
Teiji Kuzuya et al.
HEPATOLOGY RESEARCH (2019)
Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis
Atsushi Hiraoka et al.
CANCER MEDICINE (2019)
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka et al.
ONCOLOGY (2019)
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
Wan Wang et al.
CANCERS (2019)
Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma
Atsushi Yukimoto et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
Richard S. Finn et al.
JOURNAL OF HEPATOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.
Markus Peck-Radosavljevic et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function
Atsushi Hiraoka et al.
LIVER CANCER (2017)
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis
Atsushi Hiraoka et al.
DIGESTIVE DISEASES (2017)
Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma
Atsushi Hiraoka et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)
Norihiro Kokudo et al.
HEPATOLOGY RESEARCH (2015)
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update
Masatoshi Kudo et al.
ONCOLOGY (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
New contrast enhanced ultrasonography agent: Impact of Sonazoid on radiofrequency ablation
Atsushi Hiraoka et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid-enhanced MR Imaging
Katsuhiro Sano et al.
RADIOLOGY (2011)
Intraindividual Comparison of Gadoxetate Disodium-enhanced MR Imaging and 64-Section Multidetector CT in the Detection of Hepatocellular Carcinoma in Patients with Cirrhosis
Michele Di Martino et al.
RADIOLOGY (2010)
Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid
Atsushi Hiraoka et al.
ONCOLOGY LETTERS (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cumulative incidence in competing risks data and competing risks regression analysis
Haesook T. Kim
CLINICAL CANCER RESEARCH (2007)
Management of hepatoceullular carcinoma
J Bruix et al.
HEPATOLOGY (2005)
Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data
J Xie et al.
STATISTICS IN MEDICINE (2005)
分享论文
